|By Marketwired .||
|August 5, 2014 05:01 AM EDT||
SAN DIEGO, CA -- (Marketwired) -- 08/05/14 -- Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta®, requires twice daily injections. The Aegis patented Intravail® based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.
For licensing inquiries, please contact Ralph Barry.
About Aegis Therapeutics
Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.
For more information about Aegis, please visit: http://www.aegisthera.com.
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact
May. 4, 2016 07:00 PM EDT Reads: 1,262
May. 4, 2016 07:00 PM EDT Reads: 1,301
May. 4, 2016 05:30 PM EDT Reads: 1,370
May. 4, 2016 05:15 PM EDT Reads: 367
May. 4, 2016 05:00 PM EDT Reads: 1,315
May. 4, 2016 04:30 PM EDT Reads: 821
May. 4, 2016 03:30 PM EDT Reads: 620
May. 4, 2016 03:00 PM EDT Reads: 1,046
May. 4, 2016 03:00 PM EDT Reads: 1,170
May. 4, 2016 02:00 PM EDT Reads: 1,220
May. 4, 2016 02:00 PM EDT Reads: 1,275
May. 4, 2016 01:45 PM EDT Reads: 1,110
May. 4, 2016 01:45 PM EDT Reads: 1,335
May. 4, 2016 01:00 PM EDT Reads: 1,425
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
May. 4, 2016 12:45 PM EDT Reads: 613